cardiovascular diseases

News

Large study points to benefits - and risks - of GLP-1 drugs

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

News

Novo Nordisk swells alliance with AI firm Valo Health

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.

News

Safety fear halts Keros PAH trial dosing, hitting its shares

An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.

News

Cytokinetics' president and chief executive Robert Blum

FDA kicks off review of Cytokinetics' aficamten for HCM

Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy

News

MSD adds rocket fuel to Winrevair's engine in PAH

ZENITH trial of MSD's Winrevair in PAH could add further momentum to an already impressive launch

News

AI could 'cut ECG result wait times and speed up treatment'

Using artificial intelligence-powered software for screening electrocardiograms (ECGs) could deliver results more quickly and allow treatment to be started earlier, according to a new study

Large study points to benefits - and risks - of GLP-1 drugs

Novo Nordisk swells alliance with AI firm Valo Health

Safety fear halts Keros PAH trial dosing, hitting its shares

FDA kicks off review of Cytokinetics' aficamten for HCM

MSD adds rocket fuel to Winrevair's engine in PAH

AI could 'cut ECG result wait times and speed up treatment'

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

cardiovascular diseases

Editor's Picks